Nabriva Therapeutics plc
NBRVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -1,449.11% | -3,616.95% | -14,636.75% | -25,519.13% |
| EV / EBITDA | 0.08 | 0.80 | 0.50 | 0.65 |
| Quality | ||||
| ROIC | -634.43% | -78.63% | -157.94% | -102.73% |
| Gross Margin | 19.87% | 51.69% | 68.45% | 99.10% |
| Cash Conversion Ratio | 0.64 | 1.20 | 1.03 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 92.16% | 52.01% | -8.21% | – |
| Free Cash Flow Growth | 38.03% | 16.60% | 0.71% | 1.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 0.84 | 0.50 | 0.65 |
| Interest Coverage | -79.50 | -53.86 | -38.11 | -21.81 |
| Efficiency | ||||
| Inventory Turnover | 2.95 | 0.91 | 0.27 | 0.10 |
| Cash Conversion Cycle | 123.20 | 452.42 | 959.05 | -20,680.95 |